Pandemic pandemonium: pausing clinical research during the COVID-19 outbreak

Explains the effect of the COVID-19 pandemic on clinical research and provides suggestions for which studies should proceed, which should pivot to research on the pandemic, which should be paused, and which should stop.

Angiotensin receptor blockers and the risk of cancer: insights from clinical trials and recent drug recalls

Summarizes clinical trial evidence suggesting a possible link between angiotensin receptor blocker use and cancer, additional clinical evidence tending to refute a link, basic science evidence, and recent information about the problem of potentially cancer-causing impurities found in some angiotensin receptor blocker products.


We review the recent guidelines addressing the diagnosis and management of hypertension.

Hypertension hot potato — anatomy of the angiotensin-receptor blocker recalls

We provide insights into the effects of recent blood pressure medication recalls on patients, healthcare providers, and health systems.

Score one for the clinical trial data sharing experiment

Invited editorial comment on a new approach to evaluating whether patients are similar to those actually enrolled in a clinical trial, as opposed to the inclusion and exclusion criteria.

Strengthening a societal tie and other new initiatives for 2019

Editorial page describing our journal's strengthened ties with the British and Irish Hypertension Society.

Personalized medicine and the treatment of hypertension

Proposes a framework for thinking about pragmatic, one-size-fits-most treatment and highly personalized treatment of hypertension.

Adrenal vein sampling lateralization despite mineralocorticoid receptor antagonists exposure in primary aldosteronism

**Context:** Many antihypertensive medications modulate the renin-angiotensin-aldosterone system, possibly skewing the diagnosis and subtyping of primary aldosteronism (PA). Particularly, mineralocorticoid receptor antagonists (MRA) might raise renin …

Monitoring blood pressure outside of the doctor's office

We explain the approach to out-of-office blood pressure monitoring in 2018.

Out-of-office blood pressure monitoring in 2018

This patient page explains the use of 24-hour ambulatory blood pressure monitoring.